2 weeks Ago By Defense World Staff
Mainz Biomed ( NASDAQ:MYNZ – Get Free Report ) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, Marketbeat reports. HC Wainwright also issued estimates for Mainz Biomed’s Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.
06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.
23) EPS. Mainz Biomed Price Performance Shares of MYNZ stock opened at $0.23 on Monday.
The company’s fifty day simple moving average is $0.26 and its 200-day simple moving average is $0.39.
Mainz Biomed has a 52 week low of $0.19 and a 52 week high of $1.79.
About Mainz Biomed ( Get Free Report ) Read More Five stocks we like better than Mainz Biomed The Risks of Owning Bonds Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor What Is WallStreetBets and What Stocks Are They Targeting? Why Warren Buffett Is Selling: A Look at His Latest Market Moves P/E Ratio Calculation: How to Assess Stocks Why Amazon Shares May Never Trade Below $200 Again Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter ..
